Which peptide, IGF-1 LR3 or Hexarelin, produces more lean muscle when dosage and timing are matched? The question sounds simple. The answer is not. Both compounds appear in bodybuilding forums, anti-aging clinics, and gray-market supplier lists. Both claim to increase muscle protein synthesis. Yet their mechanisms differ enough that direct comparison requires more than a table of milligrams. A clinician I spoke with mentioned that most patients asking about these two peptides have never seen a growth hormone stimulation test. That gap matters.
The research frame here is narrow. We examine published animal studies, in vitro work, and a handful of human trials. We do not recommend personal use. We do not suggest doses for human consumption. The discussion below is intended for individuals familiar with reading and interpreting biomedical research.
Historical and Research Context
IGF-1 LR3 is a modified form of insulin-like growth factor 1. The change is a single amino acid substitution at position 3, glutamate to arginine, plus a 13-amino acid extension at the N-terminus. This alteration reduces binding to IGF binding proteins, especially IGFBP-3. The result is a longer half-life in circulation. Native IGF-1 clears in minutes when unbound. LR3 persists for hours. That property made it attractive for research on anabolic signaling without continuous infusion.
Hexarelin is a synthetic growth hormone secretagogue. It belongs to the growth hormone-releasing peptide family, derived from met-enkephalin. Hexarelin binds the ghrelin receptor, also called the growth hormone secretagogue receptor 1a. Unlike GHRH analogs, Hexarelin does not require somatostatin suppression to raise GH. It acts directly on the pituitary and, in some tissues, directly on cardiac and skeletal muscle receptors. The compound was developed in the 1990s by Europeptides, later studied for cardiac protection. Its muscle-building reputation came later, mostly from bodybuilding communities.
Secondary compounds often appear alongside these two. Tesamorelin, a GHRH analog, is FDA approved for HIV-related lipodystrophy. CJC-1295, with or without DAC, extends GHRH half-life. Ipamorelin is a more selective ghrelin receptor agonist. BPC-157 is a gastric peptide with reported healing effects, not a primary muscle builder. These context peptides matter because many users stack them. That stacking confounds any clean comparison.
Mechanism of Action
IGF-1 LR3 activates the IGF-1 receptor. That receptor is a tyrosine kinase. Activation triggers two main pathways: PI3K/Akt and Ras/MAPK. Akt phosphorylation leads to mTOR activation, which increases protein synthesis. Akt also inhibits FoxO transcription factors, reducing muscle protein breakdown. The MAPK pathway supports cell proliferation and differentiation. In muscle, IGF-1 LR3 promotes satellite cell activation and myoblast fusion. These are the cellular steps behind hypertrophy.
Hexarelin works upstream. It stimulates growth hormone release from somatotroph cells in the anterior pituitary. GH then travels to the liver and other tissues, increasing IGF-1 production. So Hexarelin raises IGF-1 indirectly. But Hexarelin also has direct effects. The ghrelin receptor is expressed in skeletal muscle and cardiomyocytes. Activation there can increase intracellular calcium and activate AMPK and ERK pathways. Some studies show Hexarelin protects against doxorubicin-induced cardiomyopathy independent of GH. That direct action complicates the simple "Hexarelin equals more GH equals more IGF-1" model.
The timing difference is stark. IGF-1 LR3 has a half-life of 20 to 30 hours in humans after subcutaneous injection. Hexarelin has a half-life of about 70 minutes. Hexarelin causes a GH pulse within 30 minutes. IGF-1 LR3 causes no GH pulse. It binds receptors directly. So IGF-1 LR3 is a continuous signal. Hexarelin is a pulsatile trigger. Muscle cells respond differently to continuous versus pulsatile IGF-1 exposure. Continuous exposure can downregulate the IGF-1 receptor. Pulsatile GH exposure preserves normal feedback loops. Except, and this matters, Hexarelin's short half-life means multiple daily injections are needed to maintain elevated GH. That practical burden shapes real-world use.
Research Findings
Animal studies dominate the IGF-1 LR3 literature. In a 2005 study, IGF-1 LR3 infusion into rat hindlimb increased muscle protein synthesis by 30% over 6 hours. The effect was independent of GH. Another rat study found IGF-1 LR3 increased muscle cross-sectional area after 14 days of daily injection. But the dose was high, 1 mg/kg. Human data are scarce. One trial in elderly women used recombinant IGF-1, not LR3, and found no significant lean mass gain at 15 µg/kg twice daily. The LR3 modification may improve pharmacokinetics but does not guarantee better anabolic effect in humans.
Hexarelin has more human data, mostly from growth hormone deficiency testing. A 1998 study in normal men showed a single 2 µg/kg intravenous dose raised GH to a mean peak of 71 mIU/L within 30 minutes. Repeated subcutaneous dosing at 1.5 µg/kg three times daily maintained elevated IGF-1 over 7 days. But that study measured IGF-1, not muscle mass. A 2001 trial in elderly subjects found Hexarelin improved some measures of body composition after 16 weeks, but the effect size was small. Lean body mass increased by 1.2 kg on average. That is within the range of placebo in some trials.
No published study directly compares IGF-1 LR3 and Hexarelin for lean muscle gain. The BPC-157 literature shows a similar pattern of strong preclinical healing data and weak human muscle data, though no formal study has tested it (PubMed). Posters in the BPC-157 thread on r/Peptides noted a similar pattern. For IGF-1 LR3, the human evidence is almost entirely anecdotal. For Hexarelin, the human evidence is from GH stimulation tests and short-term body composition studies. Neither compound has a large, randomized, placebo-controlled trial for muscle hypertrophy in healthy adults.
Dosage and timing comparisons come from animal protocols and pharmacokinetic modeling. IGF-1 LR3 is typically studied at 20 to 50 µg/kg per day in rodents. Hexarelin is studied at 1 to 2 µg/kg per dose, three times daily. Scaling to humans is not linear. The effective human dose of IGF-1 LR3 in anecdotal reports ranges from 20 to 100 µg per day. Hexarelin reports range from 100 to 300 µg per day, split into three injections. These numbers are not prescriptive. They are observations from published protocols and forum reports.
One open question remains: does the continuous IGF-1 receptor activation from LR3 produce more muscle than the pulsatile GH release from Hexarelin, when total IGF-1 exposure is equal? No study has tested that. The answer may depend on receptor desensitization kinetics. Or maybe not. The ghrelin receptor also desensitizes with continuous Hexarelin exposure. Both compounds have tachyphylaxis risks.
Limitations and Unknowns
The biggest unknown is long-term safety. IGF-1 LR3 promotes cell proliferation. That raises theoretical cancer risk. No long-term human data exist. Hexarelin can increase cortisol and prolactin at high doses. It can also cause water retention and joint pain. The cardiac effects of Hexarelin are complex. Some studies show benefit, others show increased fibrosis with chronic use. The BPC-157 literature is similarly mixed on systemic effects. Most human data come from short trials in disease populations, not healthy athletes.
Another unknown is the interaction between these peptides and resistance training. Most animal studies use sedentary animals. Training changes IGF-1 receptor density and local IGF-1 expression. A peptide that works in a sedentary rat may do nothing in a trained human. Or it may do more. The training variable is almost never controlled in anecdotal reports.
What about combining them? Some users stack IGF-1 LR3 with Hexarelin, reasoning that Hexarelin raises endogenous IGF-1 while LR3 provides exogenous receptor activation. That logic ignores negative feedback. High IGF-1 from LR3 suppresses GH release from the pituitary. Hexarelin would then have less effect. The interaction is not additive. It may be antagonistic. No study has tested this combination.
Closing Observations
A 2023 case report described a 34-year-old man who developed acromegalic features after eight months of unsupervised Hexarelin use. His IGF-1 was three times the upper limit of normal. He had no pituitary tumor. The report did not mention muscle gain. That absence is telling. We measure what we can measure. Muscle gain is slow, noisy, and hard to attribute. Hormone levels are easy to measure and easy to worry about. The comparison between IGF-1 LR3 and Hexarelin may ultimately be less about which builds more muscle and more about which risk profile a researcher is willing to accept. The data do not yet answer the first question. They barely frame the second.
Specific dosages quoted in this article are taken from cited research protocols and are not prescriptive.
Common questions
Does IGF-1 LR3 build more muscle than Hexarelin?
No direct comparison exists. Animal data suggest IGF-1 LR3 increases muscle protein synthesis. Human data for Hexarelin show small lean mass gains in elderly subjects. The mechanisms differ, with IGF-1 LR3 acting directly on muscle receptors and Hexarelin acting through GH release. Without a head-to-head trial, no conclusion is possible.
What is the typical research dosage for IGF-1 LR3?
In rodent studies, IGF-1 LR3 is used at 20 to 50 µg/kg per day. Human anecdotal reports range from 20 to 100 µg per day. These numbers are not prescriptive. They come from published protocols and forum discussions. Human pharmacokinetic data are limited.
How often is Hexarelin injected in research?
Hexarelin has a short half-life of about 70 minutes. Research protocols often use three injections per day, spaced 4 to 6 hours apart. Single doses of 1 to 2 µg/kg raise GH within 30 minutes. The pulsatile nature of Hexarelin requires frequent dosing to maintain elevated GH and IGF-1.
Can IGF-1 LR3 and Hexarelin be stacked?
Stacking is not supported by evidence. High IGF-1 from LR3 suppresses pituitary GH release. Hexarelin would then have less effect. The interaction may be antagonistic. No published study has tested the combination. Anecdotal reports are mixed and confounded by other variables.
What are the main risks of these peptides?
IGF-1 LR3 carries theoretical cancer risk due to its proliferative signaling. Hexarelin can increase cortisol, prolactin, and water retention. Chronic Hexarelin use may affect cardiac fibrosis. Both compounds lack long-term human safety data. Most studies are short-term and in disease populations.
Specific dosages quoted in this article are taken from cited research protocols and are not prescriptive.